BENDECTIN Drug Patent Profile

When do Bendectin patents expire, and what generic alternatives are available?

Bendectin is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in BENDECTIN is doxylamine succinate; pyridoxine hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bendectin

A generic version of BENDECTIN was approved as doxylamine succinate; pyridoxine hydrochloride by ACTAVIS LABS FL INC on August 19^th, 2016.

Summary for BENDECTIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	135
DailyMed Link:	BENDECTIN at DailyMed

US Patents and Regulatory Information for BENDECTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	BENDECTIN	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	010598-002	Approved Prior to Jan 1, 1982		DISCN	No	No

# Bendectin Market Dynamics, Financial Trajectory, Exclusivity, and Competitive Position

Last updated: August 11, 2026

Bendectin is the historical U.S. brand for a doxylamine-pyridoxine prescription product used to treat nausea and vomiting during pregnancy. Its U.S. withdrawal in 1983 created a long commercial gap, but the product returned through Duchesnay’s Diclegis launch in 2013 and Bonjesta launch in 2016. The commercial opportunity remains concentrated in a single indication, with demand driven by pregnancy rates, prescribing guidelines, payer coverage, and the availability of lower-cost alternatives.

Duchesnay is a privately held company and does not publish segment-level revenue, unit, margin, or product-profit data comparable with public pharmaceutical companies. A precise historical revenue series for Bendectin, Diclegis, or Bonjesta is therefore not publicly available. The financial trajectory is best assessed through product relaunch timing, prescription volume, pricing, reimbursement, brand competition, and generic-entry risk.

What is Bendectin and what products replaced it?

Bendectin combined doxylamine succinate and pyridoxine hydrochloride, commonly known as vitamin B6. The original U.S. product was withdrawn by Merrell Dow in 1983 after extensive litigation and declining commercial returns, although the company stated that the withdrawal was related to litigation costs and not a determination that the drug caused birth defects.

The same active-ingredient combination continued to be marketed in Canada as Diclectin. Duchesnay later obtained U.S. approval for a reformulated delayed-release product under the name Diclegis.

Product	Active ingredients	Dosage form	U.S. commercial status
Bendectin	Doxylamine succinate and pyridoxine	Delayed-release combination	Withdrawn in 1983
Diclegis	Doxylamine succinate 10 mg and pyridoxine HCl 10 mg	Delayed-release tablets	FDA approved in 2013
Bonjesta	Doxylamine succinate 20 mg and pyridoxine HCl 20 mg	Extended-release tablets	FDA approved in 2016
Diclectin	Doxylamine succinate and pyridoxine	Delayed-release combination	Marketed in Canada and other jurisdictions

Diclegis received FDA approval on April 8, 2013, for nausea and vomiting of pregnancy in women who do not respond to conservative management. Bonjesta was approved in November 2016 for the same general indication with a higher-strength tablet and a different dosing schedule. [1][2]

How large is the Bendectin market?

The Bendectin market is a niche prescription market rather than a broad pharmaceutical franchise. Its addressable population is tied to the number of pregnancies complicated by nausea and vomiting that requires prescription treatment.

Clinical literature commonly reports nausea and vomiting in approximately 50% to 80% of pregnancies, while hyperemesis gravidarum affects a much smaller subset. The commercial market includes women with persistent symptoms who do not obtain adequate relief from dietary changes, lifestyle measures, vitamin B6 alone, or off-label antiemetics. [3]

Demand has four main drivers:

1. Annual births and pregnancy rates.
2. Physician adherence to treatment guidelines.
3. Insurance coverage and patient copay levels.
4. Availability and price of generic alternatives.

The product also benefits from a narrow clinical position. Diclegis is specifically labeled for pregnancy-related nausea and vomiting, while other antiemetics may be prescribed off label. This labeling can support physician confidence, payer negotiations, and pharmacy utilization management.

The main constraint is that the active ingredients are old, inexpensive molecules. The clinical value is linked to formulation, pregnancy-specific labeling, delayed-release technology, and physician adoption rather than molecular novelty.

What was the financial trajectory after the Diclegis relaunch?

The relaunch produced a sharp change in commercial status, but public financial data remain limited.

1983 withdrawal

Bendectin’s withdrawal removed the only FDA-approved U.S. prescription product specifically combining doxylamine and pyridoxine for pregnancy-related nausea and vomiting. Litigation increased the cost of maintaining the product and created reputational and commercial pressure. The withdrawal also shifted treatment toward vitamin B6, doxylamine purchased separately, and other prescription antiemetics.

2013 Diclegis launch

Duchesnay reintroduced the combination as Diclegis after securing FDA approval. The company used the product’s pregnancy-specific labeling and delayed-release formulation to position it as a branded alternative to separate over-the-counter components.

The relaunch created several revenue levers:

• Prescription capture from patients previously using separate ingredients.
• Premium pricing for an FDA-approved branded product.
• Payer and physician support based on labeled use.
• Expansion of treatment earlier in the care pathway.
• Higher refill persistence because symptoms can continue through multiple pregnancy trimesters.

2016 Bonjesta launch

Bonjesta expanded the franchise with a higher-strength tablet. Its dosing schedule can reduce pill burden for some patients compared with Diclegis. The product gave Duchesnay a second branded asset and enabled segmentation by dose and patient preference.

Bonjesta also reduced dependence on a single SKU. The commercial benefit is limited by the fact that both products address the same indication and contain the same active ingredients.

Financial trajectory after launch

The likely commercial pattern was:

Period	Commercial development	Financial implication
1983-2012	U.S. Bendectin unavailable	No U.S. branded revenue from the product
2013-2015	Diclegis relaunch	Rapid prescription and payer-building phase
2016 onward	Bonjesta added	Portfolio expansion and dose segmentation
Generic-entry period	Lower-cost alternatives emerge	Price, volume, and market-share pressure
Mature market	Stable pregnancy-linked demand	Lower growth and greater reimbursement sensitivity

Duchesnay has not disclosed audited product revenue or profit figures in public company filings because it is private. Claims that assign precise annual Diclegis or Bonjesta sales should be treated as estimates unless supported by a named prescription database, payer dataset, or company disclosure.

What patents protect Diclegis and Bonjesta?

The commercial protection for these products is more likely to depend on formulation, dosage, manufacturing, and method-of-use rights than on composition-of-matter protection for doxylamine or pyridoxine.

The active ingredients are old and widely known. A new patent estate therefore has limited ability to block all use of the molecules. Protection can still cover:

• Delayed-release or extended-release tablet architecture.
• Specific ratios and strengths.
• Dissolution profiles.
• Stability and manufacturing processes.
• Dosing regimens for pregnancy-related nausea and vomiting.
• Combination use with dietary or clinical management protocols.
• Product-specific labeling and FDA regulatory exclusivity.

FDA approval established Diclegis as NDA 021876. Bonjesta was approved under a separate NDA. The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with approved products. Exact patent expiration dates should be taken from the current Orange Book and corresponding USPTO records rather than inferred from the product launch date. [4]

How strong is the patent estate?

The estate has moderate commercial value but limited molecular blocking power.

Its strengths are:

• Pregnancy-specific FDA approval.
• Formulation differentiation.
• Clinical and prescribing familiarity.
• Potential protection around release characteristics.
• Brand recognition associated with the Bendectin history.

Its weaknesses are:

• Old active ingredients.
• Multiple possible non-infringing formulations.
• Ability to prescribe or sell the ingredients separately.
• Potential generic competition after regulatory and patent barriers fall.
• Limited indication breadth.

A generic applicant may challenge listed patents under Paragraph IV of the Hatch-Waxman Act. A Paragraph IV certification can trigger patent litigation and, if filed within the relevant statutory period, can create a period of generic-applicant exclusivity. The commercial effect depends on the claims asserted, the patent expiration dates, pediatric extensions, settlements, and whether the generic product is therapeutically substitutable at the pharmacy level.

When does Bendectin lose exclusivity?

Bendectin itself has no current U.S. exclusivity because the original product was withdrawn decades ago. The relevant exclusivity analysis concerns Diclegis and Bonjesta.

FDA regulatory exclusivity and patent protection are separate:

• New-drug exclusivity is tied to the approval pathway and statutory eligibility.
• Patent protection depends on issued claims and expiration dates.
• Orphan-drug exclusivity does not apply to the broad pregnancy-related nausea indication.
• Pediatric exclusivity can add six months when statutory requirements are met.
• Formulation patents may expire after the underlying active ingredients have long been unprotected.

The commercial risk is therefore not a single “Bendectin expiration date.” It is a sequence involving Orange Book patents, FDA exclusivity, generic approvals, Paragraph IV litigation, and possible settlement restrictions.

What generic entry risks exist for Diclegis and Bonjesta?

Generic-entry risk is material because the active ingredients are inexpensive and chemically well established. A generic manufacturer could pursue:

• A delayed-release version equivalent to Diclegis.
• An extended-release version equivalent to Bonjesta.
• A formulation with different release characteristics but the same active ingredients.
• Separate doxylamine and pyridoxine products prescribed together.
• An alternative antiemetic under a different label.

The strongest barrier is formulation equivalence. A generic applicant must satisfy FDA requirements for pharmaceutical equivalence and bioequivalence, while the innovator can assert formulation patents. The weakest barrier is the active-ingredient level because doxylamine and pyridoxine are not novel compounds.

Generic entry could produce several effects:

Market effect	Expected consequence
Pharmacy substitution	Lower branded volume
Payer formulary changes	Higher patient cost for brand
Price competition	Lower net sales and gross margin
Physician inertia	Slower conversion in pregnancy care
Brand clinical support	Partial retention of market share
Separate-component use	Additional pricing pressure

For Bonjesta, generic competition may be more difficult if the extended-release formulation has technically distinctive dissolution or stability characteristics. That does not eliminate risk because competitors can design around particular claims or compete with other formulations.

What is the FDA and Orange Book status of Bendectin products?

Bendectin is not the current FDA-approved U.S. product name. Diclegis is the FDA-approved delayed-release product associated with the historical Bendectin combination. Bonjesta is a later FDA-approved extended-release product using the same active ingredients at higher strength.

The FDA regulatory distinction matters because:

• An approved product has labeled evidence and manufacturing controls.
• Separate over-the-counter components do not provide the same combined-product labeling.
• The Orange Book identifies approved products, therapeutic equivalence information, and listed patents.
• A discontinued or withdrawn historical brand should not be treated as an active NDA product without checking FDA records.

FDA approval does not guarantee broad reimbursement. Coverage can vary by commercial insurer, Medicaid program, prior authorization criteria, and whether the payer prefers generic or separate-component therapy.

Which companies compete with Bendectin products?

Duchesnay is the principal branded sponsor associated with Diclegis and Bonjesta in the U.S. Competition comes from several categories rather than one direct branded rival.

Direct generic competitors

Manufacturers of generic doxylamine-pyridoxine products can compete directly if they obtain approval for equivalent delayed-release or extended-release formulations.

Separate-component products

Patients and clinicians may use over-the-counter doxylamine and pyridoxine separately. This approach can be materially cheaper, although dosing, adherence, tablet splitting, and clinical supervision differ from use of the approved combination product.

Other antiemetics

Off-label or alternative prescription therapies include ondansetron, metoclopramide, promethazine, and antihistamines. These products compete for treatment decisions but do not necessarily provide the same pregnancy-specific labeling.

International products

Diclectin and related doxylamine-pyridoxine products remain important comparators in Canada and other markets. International pricing and distribution are not directly transferable to the U.S. because regulatory status, reimbursement, and product ownership differ by jurisdiction.

What licensing deals and litigation affect Bendectin?

The historical Bendectin litigation was central to the product’s U.S. withdrawal. Plaintiffs alleged an association with birth defects. Subsequent scientific reviews and epidemiologic evidence did not establish that Bendectin caused congenital malformations, and the product’s withdrawal was widely discussed as an example of litigation exposure affecting availability of a medically useful drug. [5][6]

The modern Diclegis and Bonjesta business is more likely to face:

• Patent litigation from generic applicants.
• Product-liability claims.
• Advertising and promotion disputes.
• Reimbursement and formulary disputes.
• Regulatory challenges concerning labeling or manufacturing.

No broad public revenue-sharing or major licensing transaction defines the current U.S. franchise. Duchesnay’s private ownership limits visibility into commercial agreements, royalty obligations, and product-level operating margins.

How does Bendectin compare with competing pregnancy nausea treatments?

Factor	Diclegis/Bonjesta	Separate doxylamine and pyridoxine	Ondansetron and other antiemetics
FDA-labeled pregnancy indication	Yes for Diclegis and Bonjesta	No combined-product label	Often not specifically labeled for this indication
Active ingredients	Doxylamine and pyridoxine	Same ingredients separately	Different mechanisms
Formulation	Delayed or extended release	Usually immediate-release products	Product dependent
Cost	Generally higher as branded product	Usually lower	Varies by generic availability
Patent exposure	Formulation and method claims	Limited molecule-level exposure	Product specific
Commercial differentiation	Pregnancy-specific approval	Price	Physician preference and clinical response

The brand’s central value proposition is regulatory and formulation-based. Its central commercial vulnerability is the low cost and wide availability of the underlying ingredients.

What is the revenue exposure and investment outlook?

Revenue exposure is concentrated in a narrow therapeutic market and depends heavily on brand retention. The product has defensive characteristics because pregnancy-related demand is relatively recurring at the population level and the active combination has long clinical familiarity. Growth is constrained by the absence of a broader indication strategy.

The principal financial risks are:

• Generic or authorized-generic entry.
• Payer exclusion or higher patient cost sharing.
• Substitution with separate over-the-counter ingredients.
• Declining promotional efficiency.
• Product-liability claims.
• Patent invalidity or non-infringement findings.
• Weak differentiation between Diclegis and Bonjesta.

The principal value supports are:

• Established FDA approval.
• Physician recognition.
• Pregnancy-specific clinical positioning.
• Portfolio coverage through two dosage forms.
• Potential persistence among patients who respond to the formulation.
• Limited direct competition from another large branded company.

The most likely mature-market trajectory is stable or declining branded revenue as reimbursement pressure increases and generic or low-cost alternatives gain access. Growth would require stronger payer coverage, broader international commercialization, improved evidence supporting first-line use, or a successful defense against equivalent generic formulations.

Key Takeaways

• Bendectin is the historical predecessor of Diclegis, not the current U.S. marketed brand.
• Diclegis was FDA approved in 2013; Bonjesta followed in 2016.
• The active ingredients are old, so commercial protection depends mainly on formulation, labeling, manufacturing, and method-of-use rights.
• Duchesnay’s private status prevents verification of product-level revenue, margins, and cash flow from public filings.
• Generic risk is structurally high because doxylamine and pyridoxine are inexpensive and widely known.
• The product’s main competitive advantage is pregnancy-specific FDA approval and formulation convenience.
• The major historical litigation issue was product liability surrounding alleged birth-defect risks.
• The key current diligence documents are the FDA labels, Orange Book listings, USPTO patent records, ANDA litigation dockets, payer policies, and prescription-volume datasets.

FAQs

Is Bendectin still sold in the United States?

No. The original Bendectin brand was withdrawn from the U.S. market in 1983. Diclegis and Bonjesta are the modern U.S. products containing doxylamine and pyridoxine.

Are Diclegis and Bonjesta the same drug?

They contain the same active ingredients but use different strengths and release characteristics. Diclegis uses 10 mg of each ingredient per tablet, while Bonjesta uses 20 mg of each ingredient per tablet.

Can generic doxylamine and vitamin B6 replace Diclegis?

Clinicians may prescribe or recommend the components separately, but separate products do not necessarily replicate the approved combination product’s release profile, labeling, dosing instructions, or manufacturing controls.

Did Bendectin cause birth defects?

The historical litigation alleged birth-defect risks, but scientific reviews and epidemiologic evidence did not establish that the product caused congenital malformations. The withdrawal was associated with litigation and commercial costs rather than a regulatory finding that the drug was teratogenic. [5][6]

What is the biggest commercial risk for Diclegis and Bonjesta?

The largest structural risk is generic or low-cost substitution. Because the active ingredients are old and inexpensive, brand revenue depends on formulation protection, FDA labeling, payer coverage, physician preference, and patient adherence.

References

1. U.S. Food and Drug Administration. (2013). Diclegis prescribing information.
2. U.S. Food and Drug Administration. (2016). Bonjesta prescribing information.
3. American College of Obstetricians and Gynecologists. (2018). ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. Obstetrics & Gynecology, 131(1), e15-e30.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. Brent, R. L. (1983). Bendectin: Review of the medical literature of a widely used drug. American Journal of Obstetrics and Gynecology, 145(5), 511-515.
6. McBride, W. G. (1977). Thalidomide and congenital abnormalities. The Lancet, 309(8020), 1358.